Many xenobiotic and endogenous compounds are transported from blood into hepatocytes mediated by organic anion transporter protein (OATP1B1), which is encoded by solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene. Genetic polymorphisms in SLCO1B1 gene can affect in pharmacokinetics of most compounds and may cause changes in drug efficacy and advers reactions. Thus, genetic polymorphism analysis of genes that may affect the pharmacokinetics of compounds is extremely important. The goal of this study was to determine the genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population and also to compare our results with the findings of other previously reported populations. Genotyping analyses of SLCO1B1 g.89595 T>C polymorphism was carried out in 68 healthy Turkish volunteers by a polymerase chain reactionrestriction fragment length polymorphism method. The frequencies of the TT, TC, and CC genotypes were 77.9, 19.1 and 3.0, respectively. Also, the frequencies of T and C alleles were 87.5 and 12.5, respectively. The genotype frequencies were consistent with Hardy-Weinberg equilibrium. The results of the study are compared with those of other ethnic groups, and they displayed pronounced ethnic group differences, especially East Asian and Southeast ancestry. The detection of SLCO1B1 polymorphisms may ensure benefits for adjustment of dosage regimens of some drugs and protecting from and/or decreasing adverse events, and also for future studies concerning SLCO1B1 transporter and its polymorphisms.
. INTRODUCTION
There are several factors that can affect the response to drugs, including intrinsic (non-genetic and genetic) and extrinsic factors (diet, smoking, etc.) [1] . It is estimated that genetics variation is responsible for 20 to 95% of variability in drug disposition and effects [2, 3] . Drug transporters regulate the absorption, distribution, elimination of drugs by controlling the efflux and influx of drugs in cells, and also accumulating proofs demonstrate that genetic polymorphisms of transporters may have important effects on drug safety, drug efficacy, drug disposition [1] .
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene which has alternative names SLC21A6, LST1, OATPC, OATP2 encodes organic anion transporter protein (OATP1B1) which is a membrane-bound sodium-independent protein [4] . OATP1B1 is particularly expressed in the human basolateral hepatocyte membrane [5] , where it mediates active intracellular hepatic transport of diverse anionic substrates [4, 6] . OATP1B1 is responsible for the hepatocellular uptake of not only xenobiotics like HIV protease inhibitors, HMG-CoA reductase inhibitors (statins) but also endogenous substrates like thyroid hormones, bile acids [6, 7] . Some of these substrates are listed in Table 1 .
SLCO1B1 gene is located on chromosome 12 and encodes a 691 amino acid protein with 12 transmembrane helices, and also the gene has 15 exons and 190 common variants with minor allele frequency greater than 5% [4, 6] . Many polymorphisms are identified for the human SLCO1B1 gene. One of these variant is SLCO1B1 g.89595 T>C polymorphism (rs4363657, intron 11). This polymorphism is reported to have almost complete linkage disequilibrium with SLCO1B1 c.521T>C (rs4149056) which is one of the most common variants of SLCO1B1 gene, but the linkage disequilibrium between these polymorphisms may differ between ethnicities [5] .
OATP1B1 protein has been declared to play a part in general drug disposition [8] and statin pharmacokinetics [9] . SLCO1B1 that is a significant pharmacogene is an important pharmacokinetic gene because OATP1B1 plays a significant part in transporting drugs from blood into hepatocytes [6] . Polymorphisms in the SLCO1B1 gene have been shown to effect in vitro transport function and the pharmacokinetic profile of compounds [10] . Polymorphisms in the gene that encode this protein may be related with disrupted transporter function. This can cause important inter-and intra-population variations in drug efficacy and adverse reactions.
It is known that the genotypic and allelic frequencies of SLCO1B1 polymorphisms change importantly between dissimilar populations worldwide [11] . However, to the best of our knowledge, there are no studies on this polymorphism in the Turkish population. Hence, the purpose of this study was to detect the genotypic and allelic frequencies of the SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population and also compare our findings with the findings of other previously reported population's studies. 
RESULTS
Analysis of the frequencies of the SLCO1B1 g.89595 T>C alleles and genotypes was carried out with 68 healthy unrelated individuals. As illustrated in Table 2 , of the sixty-eight subjects, 45 (66 % of them) were female, while 23 (34 % of them) were male. The body weight of the subjects participating in the study ranged 50 -107 kg and their mean body weights with standard deviation was 69.00 ± 13.01 kg. The body mass index (BMI) of the subjects varied from 17.51 to 33.69 kg/m 2 and their mean BMI with standard deviation was 24.10 ± 3.63 kg/m 2 . In addition, 52 subjects (76%) were <40 years of age, while 15 subjects (24%) were ≥40 years of age.
As demonstrated in Table 3 , the frequencies of the TT, TC, and CC genotypes in SLCO1B1 g.89595 polymorphism were 77.9, 19.1 and 3.0, respectively. Based on these results, the frequencies of T and C alleles were 87.5 and 12.5, respectively. These results were consistent with the expected genotype distributions, calculated using the Hardy-Weinberg equilibrium (p>0.05). 
DISCUSSION
Allele and genotype frequencies of SLCO1B1 g.89595 T>C polymorphism were determined in a healthy Turkish population and the results were compared with other population frequencies in this study. To our knowledge, this is the first investigation to detect this polymorphism in Turkish population. The genotype frequencies of SLCO1B1 polymorphism were 77.9% for TT, 19.1% for TC, 3.0% for CC genotypes, while the frequencies of T and C alleles were 87.5% and 12.5, respectively.
The comparison of our results with those of Hapmap Project [12] and other studies [4, 5, 11, 13] is illustrated in Table 4 . The genotype and allele frequencies of Turkish population demonstrated prominent dissimilars when compared to East Asian and Southeast ancestry. The allele frequencies of C variant were found to be significantly more common in Thai (p<0.001), Southern Han Chinese (CHS) (p<0.001), Kinh in Ho Chi Minh City in Vietnam (KHV) (p<0.001), Chinese Dai in Xishuangbanna (CDX) (p<0.001) and also Amerindian (p<0.05) compared to Turkish population. The C variant allele frequencies in these populations vary between 37.2% and 53.8% and thus are predominantly higher compared to other populations. On the other hand, no significant distinctions were noted between Turkish population and South Asian, including Bengali in Bangladesh (BEB), Punjabi in Lahore, Pakistan (PJL) and Indian Telugu in the UK (ITU) (p>0.05). The C allele frequencies ranged 7.8 -14.5 % in these populations.
Interestingly, among European ancestry, it was observed that there were statistically significant differences between Toscani in Italy (TSI) (p<0.05), Finnish in Finland (FIN) (p<0.001) and Turkish population in terms of C variant allele frequency. On the other hand, the C allele frequencies in Turkish population were similar to those reported for White ancestry including Caucasian descent, Hungarian, Roma, Czech, British in Table 4 ). The C allele frequencies in these populations vary between 10.8% and 18.0%. Hapmap Project [12] Differences in genotype and allele frequencies were examined by X 2 test. n total number of subjects. Significant at *p< 0.05 and **p < 0.001 when compared the present study.
As agreed from the above results, the frequencies of SLCO1B1 polymorphism can change importantly from population to population worldwide. Thus, this can cause important inter-and intra-population variations in drug response, drug efficacy and adverse reactions. It is known that many clinically used drugs can be transported from blood into liver mediated by OATP1B1 that is encoded by the SLCO1B1 gene polymorphism, and OATP1B1-dependent transport is a significant step in mediating drug hepatic clearance [4, 6] . Most of the studies on the association of the SLCO1B1 gene polymorphisms with drugs are related to statins, which are among the best-selling drugs worldwide [14] . Generally, statins are well tolerated [15] . However, these drugs can give rise to myopathy with signs that range from slight myalgia to rhabdomyolysis [14] . In a clinical study of 12000 patients taking simvastatin at a dose of 80 mg/day that has assessed relationship between gene polymorphisms and myopathy during statin treatment, it was reported that for SLCO1B1 g. 89595 T>C polymorphism, the odds ratio for myopathy was 4.5 (95% confidence interval 2.6-7.7) per copy of the C allele, and also this ratio was 16.9 (95% confidence interval 4.7-61.1) in subjects with CC genotypes in comparison with subjects with TT genotypes [16] . In a case report declared by Notarangelo et al. [14] , there were two cases, both of which were male. Patient 1 was 48 years old, patient 2 was 65 years old and also patient 2 was patient 1's father. Patient 1, history of coronary artery disease, suffered from quickly developing muscle pain and weakness of the extremities during therapy with 40 mg atorvastatin. In addition, patient 2 had similar symptoms as his son. It was observed that in both cases, symptoms disappeared after discontinuation of atorvastatin. These two patients were determined to be the carriers of the SLCO1B1 rs4363657 polymorphism.
Contrary to the above results, there are also studies in which polymorphism has no effect on statin side effects. In the study conducted by Hubacek et al. [13] , SLCO1B1 rs4363657 polymorphism was determined in two groups of dyslipidemia patients cured with atorvastatin or simvastatin at 10 or 20 mg/day, including subgroup who had myalgia induced by statin (n=286), and subgroup who had not myalgia/myopathy (n=707), and in control population who had not lipid-lowering therapy (n=2301). They observed that no significant was distinction among three groups for genotype frequencies of SLCO1B1, and also there was no relationship between rs4363657 polymorphism in SLCO1B1 and risk of myalgia/myopathy in low doses of statin-treated Czech patients. In addition, Kaewboonlert et al. [5] reported that there was no relationship between SLCO1B1 g.89595 T>C polymorphism and lipid-lowering response to 3 and 12 months of 20 or 40 mg/day simvastatin treatment in Thai patients with hypercholesterolaemia (n=391). It has been concluded that in lipid-lowering response to simvastatin treatment in Thai patients with hypercholesterolaemia, SLCO1B1 g.89595 T>C polymorphism should not be employed as the genetic markers.
Differences between ethnic groups may affect in individual variability, and individual variability in drug safety and efficacy is a main problem in present clinical practice, drug regulation, drug development [1, 2] . Genetic polymorphisms may make significant contributions to individualization of drug dosages, disease management, and improved therapeutics [3] .
CONCLUSION
We present evidence of the distribution of genotype and allele frequencies of SLCO1B1 polymorphism in a healthy Turkish population. The detection of polymorphisms in the mentioned gene may have benefits for adjustment of dosage regimens of some drugs and prevention from xenobiotics for precluding and decreasing adverse events, and also for future studies concerning SLCO1B1 transporter and its polymorphisms.
MATERIALS AND METHODS

Subjects
The current investigation was performed on unrelated sixty-eight Turkish healthy volunteers. The blood samples for the study were collected in Mersin City Training and Research Hospital, Mersin, Turkey. The study was approved by the Ethics Committee of Mersin University (22/10/2015, protocol no: 2015/317) and was executed according to Good Clinical Practices and the Helsinki declaration. The informed consent was taken from all the subjects who participated in the current investigation. Basic characteristics of the subjects are indicated in Table 2 .
Blood sampling and DNA extraction
Blood samples of unrelated, healthy volunteers were collected vacutainer in tubes containing heparin between 08: 00 and 10: 30 a.m. Genomic DNA extraction was performed using the Thermo Scientific Genomic DNA Purification Kit (ThermoFisher) as per the manufacturer's directives. DNA yields were detected through measurement of the absorbance at 260 nm (A260). The samples to be studied were kept at -80°C up to analysis.
Genotyping
SLCO1B1 g.89595 T>C polymorphism was performed with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method defined by Nagy et al. [4] with slight modifications. Briefly, PCR amplification for SLCO1B1 was done using the forwad and reverse primers: 5'-CAGTTTGCTAGTGTTTTGTTGAG-3' and R:5'-ACCATCCAAGACGAACAAAGAG-3', respectively. PCR was performed in a 50-μl reaction mixture which contained 400 to 600 ng of genomic DNA, 10 x PCR buffer, 1.25 mM each deoxynucleotide triphosphate, 20 ng of each primer, 1.00 unit of Taq polymerase, and 1.25 mM MgCl2 (Fermentase) on the Thermal Cycler (Thermo, UK). The PCR process was as follows: 96 ˚C for 2 min for initial denaturation, and then 35 cycles of 95°C for 30 sec, 53 °C for 30 sec, 72 ˚C for 30 sec, followed by a final elongation at 72°C for 5 min. In order to ensure the use of contaminant DNA-free reagents, each PCR analysis included negative control reactions. PCR products (369 bp) were electrophoresed on a 2 % agarose gel including ethidium bromide (500 ng/ml) which made the products visible, and then the 10 μl PCR product was cut in 15 minutes at 37°C using 10 U of Fast Digest Kpn I restriction enzyme with the proper buffer in total volume of 20 μl. The T allele was digested to 236 and 133 bp fragments while the C allele was digested to 152, 133 and 84 bp on 3 % agarose gel with ethidium bromide was used to evaluate the digested fragments. For a quality assurance, 10% of the samples at random was reanalyzed, which provide 100% concordance.
Statistical analysis
Allelic and genotypic frequencies were calculated using genotype counting method. The expected and observed frequencies of SLCO1B1 gene were compared using the chi-square (X 2 ) test based on Hardy-Weinberg equilibrium. X 2 test was employed to compare the genotype and allele frequencies determined from the current investigation with those in other populations. Statistical analysis were performed using IBM SPSS computer software for Windows 25.0. p<0.05 and <0.001 were accepted statistically significant.
